Asher Hackett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Asher Hackett has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Orit Yossepowitch
Infectious Disease Unit, Edith Wolfson Medical Center, Halochamim 62, Holon 5822012, Israel
1 shared publication - Orna Schwartz
Microbiology and Immunology Laboratory, Edith Wolfson Medical Center, Holon 5822012, Israel
1 shared publication - Rivka Sheffer
Tel Aviv Health District, Ministry of Health, Tel Aviv 6473904, Israel
1 shared publication - Yael Goor
Levinski Clinic of the Tel Aviv District Office, Ministry of Health, Tel Aviv 6699001, Israel
1 shared publication - Yarden Weiss
Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel
1 shared publication - Yasmin Maor
Infectious Disease Unit, E. Wolfson Medical Center, HaLochamim St. 62, Holon 5822012, Israel
1 shared publication
Latest Publications
- Open Access
- 21 August 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (16) , 4924
Prevalence and Risk Factors for Antimicrobial Resistance of Mycoplasma genitalium Infections in a High-Risk Population
Background/Objectives: Mycoplasma genitalium (MG) infections and antibiotic resistance are increasing in prevalence while treatment options are limited. Limited data exist regarding MG resistance in Israel. Our aim was to study the prevalence of MG resistance in a sexually transmitted infection (STI) clinic in Israel. Methods: We performed a single-center retrospective study among patients attending an STI clinic during 2019–2020. MG isolates were tested to detect their resistance to azithromycin and fluoroquinolones (FQs) using commercial kits (Allplex™ MG & AziR Assay, Allplex™ MG & MoxiR Assay). We collected patient data regarding the risk factors for STIs and resistance. A multivariate logistic regression model was used to identify the risk factors for resistance. Results: Of the 142 patients who tested positive for MG, 50 (35.2%) and 22 (15.5%) had resistant mutations to azithromycin and FQ, respectively, and 13 (9.2%) showed resistance to both agents. In a multivariate logistic regression model, men who have sex with men (RR 7.01 95% CI 3.00–16.33) and past STIs (RR 2.33 95% CI 1.01–5.34) were independent risk factors for azithromycin resistance. Conclusions: We found a high prevalence of azithromycin resistance and, to a lesser degree, FQ resistance. These findings may help design the treatment guidelines and support routine resistance testing in high-risk populations.
- 21 August 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (16) , 4924
Open AccessPrevalence and Risk Factors for Antimicrobial Resistance of Mycoplasma genitalium Infections in a High-Risk Population
Background/Objectives: Mycoplasma genitalium (MG) infections and antibiotic resistance are increasing in prevalence while treatment options are limited. Limited data exist regarding MG resistance in Israel. Our aim was to study the prevalence of MG resistance in a sexually transmitted infection (STI) clinic in Israel. Methods: We performed a single-center retrospective study among patients attending an STI clinic during 2019–2020. MG isolates were tested to detect their resistance to azithromycin and fluoroquinolones (FQs) using commercial kits (Allplex™ MG & AziR Assay, Allplex™ MG & MoxiR Assay). We collected patient data regarding the risk factors for STIs and resistance. A multivariate logistic regression model was used to identify the risk factors for resistance. Results: Of the 142 patients who tested positive for MG, 50 (35.2%) and 22 (15.5%) had resistant mutations to azithromycin and FQ, respectively, and 13 (9.2%) showed resistance to both agents. In a multivariate logistic regression model, men who have sex with men (RR 7.01 95% CI 3.00–16.33) and past STIs (RR 2.33 95% CI 1.01–5.34) were independent risk factors for azithromycin resistance. Conclusions: We found a high prevalence of azithromycin resistance and, to a lesser degree, FQ resistance. These findings may help design the treatment guidelines and support routine resistance testing in high-risk populations.